ReviewNature communications2025
Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance.
Review in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Bacteriophages in the treatment of cutaneous infections and skin disorders: therapeutic advances and future directions.Clinical microbiology reviews · 2026Review
- Development and clinical validation of a CRISPR/Cas9-engineered reporter phage cocktail for rapid detection ofMicrobiology spectrum · 2026Article
- AI-assisted phage formulation delivered via injectable hydrogels for localized control of implant-associated infections.Bioactive materials · 2026Article
- UropathogenicAntibiotics (Basel, Switzerland) · 2026Review
- Rapid and quantitative measurement of bacteriophage infectivity via fully automated droplet digital PCR.Nature communications · 2026Article
- Profiling the gut resistome to unlock antimicrobial resistance biology and inform clinical risk.Nature communications · 2026Review
- From screening to treatment:Microbiology spectrum · 2026Article
- Artificial Intelligence in Bacteriophage Science: A Comprehensive Narrative Review of Applications, Challenges, and Translational Opportunities.Antibiotics (Basel, Switzerland) · 2026Review
- Bacteriophages as Potential Sustainable Alternatives to Antibiotics for ControllingAntibiotics (Basel, Switzerland) · 2026Review
- Translational Quantitative Proteomic Assay for Bacteriophages: A New Frontier in Phage Pharmaceutical Development.bioRxiv : the preprint server for biology · 2026Article
- Engineered phages evade the complete defense repertoire of highly phage-resistant MRSA clinical isolates.bioRxiv : the preprint server for biology · 2026Article
- Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.Pharmaceutics · 2026Review
- Review
- Lipopolysaccharide-targeting treatments for multidrug-resistantExpert opinion on therapeutic targets · 2026Review
- Review
- Phage-Based Approaches to ChronicAntibiotics (Basel, Switzerland) · 2026Review
- Phage PM16 Therapy Induce Long-Term Protective Immunity AgainstPathogens (Basel, Switzerland) · 2026Article
- The subgingival microbiome in periodontitis: from ecological dysbiosis and metabolic reprogramming to precision interventions.Frontiers in microbiology · 2026Review
- Exploring phages through play: creative 3D models for science engagement.Access microbiology · 2026Article
- Functional genetic signatures of the gut microbiome in cardiometabolic diseases: mechanisms and translational opportunities.Frontiers in microbiomes · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amid rising antimicrobial resistance and limited antibiotic innovation, bacteriophages are gaining attention as potential therapeutics across human health, animal, and food sectors. Despite historical use, their clinical application in humans remains constrained by scientific, industrial, and regulatory challenges. To address these issues, the Transatlantic Task Force on Antimicrobial Resistance (TATFAR) convened sessions with experts from member parties. This perspective synthesizes insights from the TATFAR group, highlighting regulatory differences, research gaps, and opportunities for international collaborations to advance bacteriophage therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.